Cargando…

The association between diet and glucocorticoid treatment in patients with SLE

BACKGROUND: Some studies suggest that the risk for and severity of systemic lupus erythematosus (SLE) can be modified by certain nutrients. The aim of this study was to investigate the association between diet and glucocorticoid (GC) treatment, as a proxy for disease activity, in patients with SLE....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lourdudoss, Cecilia, Hafström, Ingiäld, Frostegård, Johan, van Vollenhoven, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731837/ https://www.ncbi.nlm.nih.gov/pubmed/26848399 http://dx.doi.org/10.1136/lupus-2015-000135

Ejemplares similares

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case–control study over 10 years
por: Ajeganova, Sofia, et al.
Publicado: (2021)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
por: Levitsky, Adrian, et al.
Publicado: (2017)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2017)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
por: Davidson, Julie E, et al.
Publicado: (2018)

Similar progression of carotid intima–media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
por: Ajeganova, Sofia, et al.
Publicado: (2020)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance
por: Ploran, Elisabeth, et al.
Publicado: (2019)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
por: Nived, Ola, et al.
Publicado: (2020)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres
por: Tani, Chiara, et al.
Publicado: (2018)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study
por: Drenkard, Cristina, et al.
Publicado: (2020)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9k8iuppiffrhsohbil03qcaq9